Spruce Biosciences, Inc. financial data

Symbol
SPRB on OTC
Location
611 Gateway Boulevard, Suite 740, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 228 % -51.7%
Debt-to-equity 81.8 % +166%
Return On Equity -305 % -392%
Return On Assets -168 % -254%
Operating Margin -7.1K % -1066%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.07M shares -97.4%
Common Stock, Shares, Outstanding 563K shares -98.6%
Entity Public Float 18.8M USD -74.9%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 563K shares +2.26%
Weighted Average Number of Shares Outstanding, Diluted 563K shares +2.26%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 697K USD -90.2%
Research and Development Expense 36.9M USD +2.26%
General and Administrative Expense 13.3M USD -6.81%
Operating Income (Loss) -49.5M USD -14.4%
Net Income (Loss) Attributable to Parent -47.9M USD -21.4%
Earnings Per Share, Basic 13 USD/shares +7.43%
Earnings Per Share, Diluted 13 USD/shares +7.43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.7M USD -82.2%
Cash, Cash Equivalents, and Short-term Investments 10.7M USD -82.2%
Accounts Receivable, after Allowance for Credit Loss, Current 15M USD
Other Assets, Current 2.92M USD +239%
Assets, Current 14.5M USD -77.2%
Other Assets, Noncurrent 62K USD -88.3%
Assets 15.3M USD -76.5%
Accounts Payable, Current 1.39M USD -23%
Accrued Liabilities, Current 7.5M USD -3.08%
Liabilities, Current 9.43M USD -20.5%
Operating Lease, Liability, Noncurrent 500K USD
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 9.93M USD -26.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -275M USD -21.1%
Stockholders' Equity Attributable to Parent 5.39M USD -89.6%
Liabilities and Equity 15.3M USD -76.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.7M USD +14.9%
Net Cash Provided by (Used in) Financing Activities -411K USD -81.1%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 563K shares -98.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.7M USD -82.2%
Deferred Tax Assets, Valuation Allowance 85.3M USD +27.1%
Deferred Tax Assets, Gross 85.5M USD +26.9%
Operating Lease, Liability 1.02M USD -19.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -53M USD -12%
Lessee, Operating Lease, Liability, to be Paid 1.16M USD -22.8%
Operating Lease, Liability, Current 283K USD +12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 365K USD +3.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 354K USD +3.21%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 140K USD -39.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 376K USD +3.01%
Deferred Tax Assets, Operating Loss Carryforwards 35.5M USD +6.24%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.35M USD +34.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 64K USD -83%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 197K USD -20.9%
Share-based Payment Arrangement, Expense 1.84M USD -67.1%
Interest Expense 140K USD -60.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%